HALOZYME THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period
HALOZYME THERAPEUTICS, INC. (HALO) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period of 276.34 thousand shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-17.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod · last filed 2026-02-17
- HALOZYME THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2025 was 276.34K shares, a 33.27% decline from fiscal 2024.
- HALOZYME THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2024 was 414.13K shares, a 15.25% increase from fiscal 2023.
- HALOZYME THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2023 was 359.33K shares, a 38.17% decline from fiscal 2022.
- HALOZYME THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2022 was 581.19K shares, a 78.92% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 12 month |
|---|---|
| 2025-12-31 | 276.34K shares 10-K · filed 2026-02-17 |
| 2024-12-31 | 414.13K shares 10-K · filed 2025-02-18 |
| 2023-12-31 | 359.33K shares 10-K · filed 2024-02-20 |
| 2022-12-31 | 581.19K shares 10-K · filed 2023-02-21 |
| 2021-12-31 | 324.83K shares 10-K · filed 2022-02-22 |
| 2020-12-31 | 2.81M shares 10-K · filed 2021-02-23 |
| 2019-12-31 | 979.65K shares 10-K · filed 2020-02-24 |
| 2018-12-31 | 1.29M shares 10-K · filed 2019-02-21 |
| 2017-12-31 | 1.19M shares 10-K · filed 2019-02-21 |
| 2016-12-31 | 955.05K shares 10-K · filed 2019-02-21 |
| 2015-12-31 | 407.94K shares 10-K · filed 2018-02-20 |
| 2014-12-31 | 1.19M shares 10-K · filed 2017-02-28 |
| 2013-12-31 | 214.98K shares 10-K · filed 2016-02-29 |
| 2012-12-31 | 260.72K shares 10-K · filed 2015-03-02 |
| 2011-12-31 | 593.29K shares 10-K · filed 2014-02-28 |
| 2010-12-31 | 682.52K shares 10-K · filed 2013-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |